Compare GBX & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBX | LTGO |
|---|---|---|
| Founded | 1974 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1996 | 2026 |
| Metric | GBX | LTGO |
|---|---|---|
| Price | $43.04 | $20.82 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 316.8K | 218.2K |
| Earning Date | 04-07-2026 | N/A |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 28.02 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $3,240,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.74 | N/A |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.23 | $17.22 |
| 52 Week High | $59.19 | $25.93 |
| Indicator | GBX | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 44.55 |
| Support Level | $41.27 | N/A |
| Resistance Level | $48.66 | $20.49 |
| Average True Range (ATR) | 0.90 | 1.86 |
| MACD | 0.15 | -0.36 |
| Stochastic Oscillator | 82.73 | 7.31 |
Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.